ArticleLiver international : official journal of the International Association for the Study of the Liver2020
Optimization of hepatitis C virus screening strategies by birth cohort in Italy.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations.Applied health economics and health policy · 2022Pooled it
- Evaluation of the hepatitis c virus screening program in the Marche Region (Italy): experience from the Pesaro-Urbino health authority.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Hepatitis Free Hospital: Retrospective Results of an In-Hospital Project of Hepatitis C Virus Micro-Elimination.Viruses · 2026Article
- Uncovering hidden HCV infections in adults over 55: reflex testing and insights for opportunistic screening in a tertiary care setting.Archives of public health = Archives belges de sante publique · 2026Article
- Hepatitis C Screening: A Health Technology Assessment.Ontario health technology assessment series · 2026Article
- Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia.PLOS global public health · 2026Article
- Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study.Pathogens (Basel, Switzerland) · 2025Article
- Prevalence of Hepatitis C in the Emilia-Romagna Region of Italy: Population-Wide Screening.Viruses · 2025Article
- The Disease and Economic Burden of HBV and HCV in Ethiopia.Journal of viral hepatitis · 2025Review
- Prevalence of Hepatitis C Virus Among Hospitalized Patients in a Tertiary Hospital in Italy: The Basis for a National Screening Assessment Model?Microorganisms · 2025Article
- Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.Viruses · 2024Review
- Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience.Viruses · 2023Article
- Exploring Knowledge and Awareness of HCV Infection and Screening Test: A Cross-Sectional Survey Among an Italian Sample.Journal of community health · 2023Article
- Hepatitis C Virus Micro-Elimination Plan in Southern Italy: The "HCV ICEberg" Project.Pathogens (Basel, Switzerland) · 2023Article
- Increasing and sustaining blood-borne virus screening in Spain and Portugal throughout the COVID-19 pandemic: a multi-center quality improvement intervention.Frontiers in public health · 2023Article
- Article
- Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCost-effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost-effective in Italy.
methodsA model was developed to quantify screening and healthcare costs associated with HCV. The model-estimated prevalence of undiagnosed HCV was used to calculate the antibody screens needed annually, with a €25 000 cost-effectiveness threshold. Outcomes were assessed under the status quo and a scenario that met the World Health Organization's targets for elimination of HCV. The elimination scenario was assessed under five screening strategies.
resultsA graduated birth cohort screening strategy (graduated screening 1: 1968-1987 birth cohorts, then expanding to 1948-1967 cohorts) was the least costly. This strategy would gain approximately 144 000 quality-adjusted life years (QALYs) by 2031 and result in an 89.3% reduction in HCV cases, compared to an 89.6%, 89.0%, 89.7% and 88.7% reduction for inversed graduated screening, 1948-77 birth cohort, 1958-77 birth cohort and universal screening, respectively. Graduated screening 1 yielded the lowest incremental cost-effectiveness ratio (ICER) of €3552 per QALY gained.
conclusionsIn Italy, a graduated screening scenario is the most cost-effective strategy. Other countries could consider a similar birth cohort approach when developing HCV screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.